key: cord-1021055-hmg1ng3m
authors: Romero, Juan Pablo; Bravo-Martín, Ana; Oliva-Navarrete, Paulina; Sánchez-Cuesta, Francisco; Ríos-Lago, Marcos; Benito-León, Julián
title: Impact of COVID-19 on a brain damage unit
date: 2021-06-06
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2021.05.036
sha: e574ba8b52edd00388b2e962922dc16d9aa998a9
doc_id: 1021055
cord_uid: hmg1ng3m

AIM: To report on the impact of COVID-19 on a brain damage unit. METHODS: We reviewed the records of all patients admitted to our brain damage unit. The study included all the significant clinical events from the first RT-PCR assay (April 8th, 2020) for SARS-CoV-2 to the day all patients tested negative (June 8th, 2020). RESULTS: Of the 20 patients (14 men) (age 57.7 ± 14.9; 2–71 months after brain damage; all with a Rankin scale > 4), 16 tested positive for SARS-CoV-2 and remained positive for a mean of 32.3 days (ranging from 26 to 61). One patient died from COVID-19, while 12 patients were asymptomatic and three suffered mild pneumonia without acute respiratory distress syndrome. All patients received prophylactic subcutaneous heparin. Intravenous methylprednisolone was prescribed for three patients with bilateral pneumonia with excellent results. CONCLUSIONS: Most positive cases (93.7%) were not severe. The good outcome was most likely due to the use of phylactic anticoagulation therapy, the early use of methylprednisolone for pneumonia, and the previously reported immunosuppression amid patients with brain damage. This study hopes to encourage further study into brain damage immunity.

The havoc caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has strained to the limit the ability of scientists worldwide to find effective treatments, elucidate pathophysiological mechanisms and identify severity markers. [1] [2] [3] The mortality from SARS-CoV-2 is largely due to bilateral pneumonia, associated with an exaggerated immune response leading to acute respiratory distress syndrome. This is occasionally combined with hypercoagulability state and multisystemic failure (elevated levels of IL6, C reactive protein, ferritin, and Ddimer). [4] [5] Many old time-tested drugs for the disease have empirically "repurposed" for treatment. [6] [7] [8] One of the most used, in the initial phase, was hydroxychloroquine, [6, 7] although it has subsequently proved to be ineffective and have severe and life-threatening adverse effects. [9] Currently, the only treatment that has been shown to reduce mortality is dexamethasone. [10] Several comorbidities have been identified as potential susceptibility factors for severe infection and fatal outcomes, such as the preexistence of diabetes, arterial hypertension, obesity, malnutrition, restrictive and obstructive airway diseases, and low vitamin D levels among others. [5, [11] [12] [13] Some of these factors are commonly seen in patients admitted to brain damage units.

Patients with long-term hospital stay following stroke or traumatic brain injury patients are at increased risk of more severe infection due to the preexistence of malnutrition, low vitamin D levels and reduced respiratory capacity. [14] [15] [16] However, there is no reliable information on the impact of J o u r n a l P r e -p r o o f COVID-19 on patients with brain damage. [3] We hereby report the impact of COVID-19 impact on a brain damage unit with 20 hospitalized patients, of whom 16 were affected.

In this retrospective observational study, we reviewed the records of all patients admitted to our brain damage unit. The study includes all significant clinical events from the first positive qualitative real-time reverse-transcriptasepolymerase-chain-reaction (RT-PCR) assay (April 8th, 2020) for SARS-CoV-2 to the day all patients were tested negative (June 8th, 2020). Daily chest auscultation, monitoring of temperature, respiration rate, oxygen saturation, and heart rate were recorded for all patients. Laboratory values of blood cell count, renal, and liver functions were only registered for positive patients. Ferritin, Ddimer, and C reactive protein levels were determined in 15 out of the 16 positive patients. Chest X-rays were only performed on patients with dyspnea or oxygen saturation below 94%. Blood tests or chest X-rays were not given to negative patients.

Basal laboratory data from the last six months (vitamin D, total protein, albumin, vitamin B12, folic acid, thyroid stimulating hormone, ferritin, liver enzymes, creatinine, triglycerides, and total cholesterol) and any invasive procedures, diagnosed infections, and bacterial cultures in the last year were obtained from the clinical history of every patient.

This study was performed retrospectively with anonymized clinical data.

The legal guardians of all participants provided their informed consent to participate in this study, J o u r n a l P r e -p r o o f

The clinical and laboratory data of the participants was compared using Student's t-tests and Mann-Whitney U tests or Fisher's exact test, when appropriate, for quantitative and nominal variables, respectively. A Kolmogorov-Smirnov test was used to verify normality while the correlations between clinical and laboratory data in positive patients were identified using Spearman's correlation coefficients.

All analyses were performed using SPSS v 19.0. (IBM Corp., Armonk, NY, USA) with a significance level of p <0.05.

On April 8th, 2020 (date of the diagnosis of the first case), the mean age of the 20 patients [14, (70%) men] in the brain damage unit was 57.7 years (range: 22-84 years). The mean time (months) since the brain injury was 10.4 (range: 2 to 70) and all had a modified Rankin scale score > 4. Additional demographic data is provided in Table 1 .

The first patient to be diagnosed was case number 15. SARS-CoV-2 infection was suspected because of fever (38ºC) and malaise for 48 hours. The patient's nasopharyngeal swab test for SARS-CoV-2 by RT-PCR assay was positive on April 8th; the remaining 19 patients were then tested for COVID-19 using the same method, resulting in 15 positives for SARS-CoV-2. The four negative patients were tested up to three times over the following 10 days, all testing persistently negative. However, these patients were isolated and quarantined in a separate area of the hospital but remained in direct supervision Leukopenia was detected in two patients, both had slightly elevated levels of ferritin (less than 2 times the higher limit set by our laboratory) and moderately elevated C reactive protein; D-dimer levels were otherwise normal. Among the three patients who developed pneumonia, only one had slightly elevated Ddimer levels, while all showed elevated C reactive protein levels (lower than 6 mg/dL) (reference value < 0.5). Two out of three patients had low vitamin D levels. All of them received antibiotic treatment, according to the antibiogram, for six days and respiratory symptoms abated before treatment was ended.

Among the positive cases some basal (before the outbreak) analytic alterations were found. Low vitamin D (11 patients), low vitamin B12 levels (two patients), total protein levels (four patients), high thyroid stimulating hormone (three patients), alteration in liver enzymes non-superior to three times the normal values (three patients), and high cholesterol or triglyceride levels (four patients). None of the negative cases had alterations in these values except one patient who had high cholesterol levels and three with low vitamin D levels.

However, there were no differences between basal laboratory values (vitamin D, total protein, albumin, vitamin B12, folic acid, thyroid stimulating hormone, ferritin, liver enzymes, creatinine, triglycerides, and total cholesterol) among Table 2 .

Finally, days to negative RT-PCR assay ranged from 26 to 61 with a mean of 32.3±11.6 days. The time to resolve the infection (i.e., negative RT-PCR) was not correlated with any alteration in clinical or laboratory data (Spearman's correlation coefficients, all p > 0.05).

The outcome of the SARS-CoV-2 outbreak in this cohort is unexpected.

Despite having premorbid severe disabilities (arterial hypertension, diabetes mellitus, heart disease, chronically disabled and hospitalized patients) which are well-established risk factors for fatal outcome in SARS-CoV-2 infection, [18, 19] in majority of them, most of the positive cases (93.7%) did not have a severe affection.

Given our prediction of a severe or fatal outcome, all infected patients, regardless of symptoms, were empirically treated with hydroxychloroquine and acetylcysteine, based on the best available evidence and previous experience with such patients [20] The mild respiratory infections and good outcome in the three most severely symptomatic patients were surprising.

There are several hypotheses that we propose for the good outcome of our patients. The first is the possible protective role that prophylactic J o u r n a l P r e -p r o o f anticoagulation therapy could play, given that thrombotic or thromboembolic events have been established as part of the core physiopathology of COVID-19. [21, 22] On the other hand, patients with brain damage reportedly have immunosuppression due to as yet unknown processes. [23] Moreover, a specific monocyte deactivation, with decreased capacity for antigen presentation and depressed secretion of proinflammatory cytokines, has been documented. [24] This is in line with the important role that these cells may have in the dysregulated inflammation in SARS-CoV-2 infection [25] and findings of a possible beneficial role of disease-modifying therapies among multiple sclerosis patients. [26] The history of invasive procedures and positive bacterial cultures in our patients is in keeping with the previously reported immune suppression related to brain damage. [23] Thus, we cannot rule out an immune modulator role of the bacteria, mainly gram-negatives. [27] Of further interest is the prolonged virus clearance in RT-PCR assays (32.3 days) in our patients compared to general population (10.5 days). [28] Further research is required into the role of brain-damage associated immune suppression in cases of SARS-CoV-2.

Finally, we should consider the possibility of varying degrees of virulence in active variants of SARS-CoV-2. [29] A less virulent variant would explain why none of our patients had an adverse outcome from the disease.

Our findings are in line with those of other studies of highly disabled, spinal injury patients whose outcomes were better than expected [30] . Immune suppression was also been reported [31] in these patients.

We recognize that a principal limitation of this study is the absence of chest X-rays for most positive patients. However, chest X-rays were only performed on those with symptoms of respiratory impairment. This study also J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f The good outcome could be related to anticoagulation therapy, methylprednisolone and prevailing immunosuppressed state.

Further studies on immune-modulatory effects of brain damage are required.

J o u r n a l P r e -p r o o f

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (jbenitol67@gmail.com).

Signed on behalf of all authors as follows:

Dr. Julián Benito-León

Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2

Using Unsupervised Machine Learning to Identify Age-and Sex-Independent Severity Subgroups among COVID-19 Patients in the Emergency Department

Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

Full spectrum of COVID-19 severity still being depicted

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Famotidine Against SARS-CoV2: A Hope or Hype?

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Obesity Is a Risk Factor for Severe COVID-19 Infection

Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity

Vital capacity following traumatic brain injury

Injury and Quality of Life: A Prospective, Observational Study

Clinical malnutrition in severe traumatic brain injury: Factors associated and outcome at 6 months

Acute respiratory distress syndrome subphenotypes and therapy responsive traits among preclinical models: protocol for a systematic review and meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Triple jeopardy: disabled people and the COVID-19 pandemic

Treatment options for COVID-19: The reality and challenges

COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure

Cerebral venous thrombosis in COVID-19

Nosocomial infections and immunity: lesson from brain-injured patients

Transient monocyte release of interleukin-10 in response to traumatic brain injury

Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology

Bar-Or A. COVID-19 and MS disease-modifying therapies

Roles of Capsule and Lipopolysaccharide O Antigen in Interactions of Human Monocyte-Derived Dendritic Cells and Klebsiella pneumoniae

Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection

Geneva Center for Emerging Viral Diseases. Novel SARS-CoV-2 variants: the pandemics within the pandemic

Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury

Spinal cord injuryinduced immunodeficiency is mediated by a sympathetic-neuroendocrine adrenal reflex